| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Tivozanib |
| Brand | Fotivda® |
| Indication | For the first line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC. |
| Assessment Process | |
| Rapid review commissioned | 09/01/2019 |
| Rapid review completed | 24/01/2019 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tivozanib compared with the current standard of care. |
The HSE has approved reimbursement following confidential price negotiations August 2019.
